SABCS Conference Report

Featured:

Update on Novel Agent from the DESTINY-Breast01 Trial

How to Avoid Chemotherapy Overtreatment in Breast Cancer

First Immunotherapy Combo Well-Tolerated

Phase 3 MonarchE Trial: Efficacy Continues